Exelixis, Inc. — Form 10-Q Summary
Period clarification: The request metadata says 2022 Q3, but the filing is for the quarter ended September 29, 2023 (presented as September 30, 2023). Comparisons below are against 2022.
Business context and reporting period
Exelixis is an oncology company whose revenues primarily depend on cabozantinib, sold in the U.S. as CABOMETYX and COMETRIQ and commercialized internationally through partners. The company also markets or licenses COTELLIC and MINNEBRO and is developing a pipeline including zanzalintinib, XB002 and other candidates. The filing covers the third quarter and first nine months of fiscal 2023.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $471.9 million | $411.7 million | $1,350.6 million | $1,187.1 million |
| Net product revenue | $426.5 million | $366.5 million | $1,199.5 million | $1,023.8 million |
| Operating income (loss) | $(17.6) million | $82.6 million | $89.1 million | $249.6 million |
| Net income | $1.0 million | $73.2 million | $122.2 million | $212.5 million |
| Diluted EPS | $0.00 | $0.23 | $0.38 | $0.65 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $322.8 million | $288.9 million |
Q3 gross margin was 96%, unchanged year over year. Research and development expense rose 67% to $332.6 million in Q3, including an $80 million upfront payment for the Insilico license; selling, general and administrative expense increased 20% to $138.1 million. Interest income was $23.1 million in Q3, helping offset the operating loss. The Q3 effective tax rate was 82.1%, versus 20.5% a year earlier, in part because of nondeductible executive compensation and the branded prescription drug fee, partially offset by tax credits.
At September 30, cash, cash equivalents and investments totaled $1.915 billion, down from $2.067 billion at December 31, 2022. Working capital was $1.067 billion. Total liabilities were $629.3 million, including $190.9 million of long-term operating lease liabilities; the filing presents no borrowings or other financial debt. For the first nine months, investing cash flow was $(88.7) million and financing cash flow was $(339.9) million, including $341.1 million of cash paid for share repurchases. The company stated its available resources and expected revenues should fund operations for at least 12 months and thereafter for the foreseeable future.
Material changes versus the prior comparable period
- Q3 total revenue increased 15%; net product revenue increased 16%. CABOMETYX revenue rose 17% to $422.2 million, driven by higher unit volume and average net selling price. COMETRIQ revenue declined 15% to $4.3 million.
- Despite higher revenue, Q3 operating income swung to a $17.6 million loss, mainly as R&D expense increased substantially. Nine-month net income declined 42% to $122.2 million.
- Collaboration services revenue fell 72% in Q3 to $3.1 million and 55% for the nine-month period, principally reflecting lower development cost reimbursements.
- Nine-month operating cash flow increased to $322.8 million from $288.9 million, while cash and investments declined, primarily reflecting repurchases, pipeline investment and operating expenditures.
- The company repurchased 16.9 million shares for an aggregate $344.8 million through September 30; approximately $205.2 million remained under its $550 million 2023 authorization.
Outlook, commentary, risks and unusual items
- Management projected net product revenue could increase for the remainder of 2023 versus the prior year period, while collaboration services revenue could decrease. It expected R&D expense to decrease versus the prior-year period as upfront license fees fall, partly offset by personnel and clinical-trial costs; SG&A could increase. The filing provides no specific full-year revenue or earnings guidance.
- Management identified continued CABOMETYX commercial success as central to funding operations and growth. Key risks include competition, payer coverage and pricing pressure, clinical-trial outcomes, regulatory approvals and the possibility of generic CABOMETYX entry.
- CONTACT-02 met its PFS primary endpoint in previously treated metastatic castration-resistant prostate cancer; interim overall-survival data were immature and not statistically significant. COSMIC-313 met its PFS endpoint, but interim OS analyses had not met the statistical-significance threshold; further analysis was planned. Management intended to discuss potential regulatory submissions with the FDA after subsequent OS analyses.
- The CABINET phase 3 study was stopped for enrollment and unblinded after the independent monitoring board observed significant efficacy improvements. Exelixis planned FDA discussions following presentation of results.
- Teva litigation was settled, with a license for U.S. generic CABOMETYX marketing beginning January 1, 2031, subject to FDA approval and agreement conditions. MSN II trial judgment was expected in the first half of 2024; Cipla litigation remained stayed. The company stated an unfavorable generic-litigation outcome could materially harm CABOMETYX revenue and that potential loss estimates were not determinable.
- The Insilico agreement included an $80 million upfront payment for XL309, recognized as R&D expense, plus potential development and commercial milestones and royalties. Across certain in-licensing and asset-purchase arrangements, potential future milestone payments were substantial: up to $774.0 million for development, $615.2 million for regulatory and $3.9 billion for commercial milestones, in aggregate per product or target.
- Management reported modest effects on clinical-development operations from political tensions and hostilities, including the Israel-Hamas conflict. It also highlighted uncertainty around clinical execution, reimbursement, competition and future pipeline development.
Important facts for investors to verify
- Whether CABOMETYX volume growth, pricing and international royalties continue to offset higher discounts, rebates and competitive pressures.
- Upcoming CABINET, CONTACT-02 and COSMIC-313 overall-survival, regulatory and commercial developments, and the status of zanzalintinib and other pipeline trials.
- Outcomes and timing of the MSN II and Cipla patent matters, and the practical implications of the Teva settlement’s January 2031 license date.
- R&D spending and future milestone commitments after the unusually large license-related expense in Q3.
- Use of remaining repurchase authorization relative to investment needs, cash generation and the stated liquidity outlook.